CoChat
Sign Up
Cited by 37Pharmacogenetics and Drug MetabolismGenetic Associations and EpidemiologySchizophrenia research and treatment

Pharmacogenomic Biomarkers and Their Applications in Psychiatry

Open access
Kam, Heejin, Jeong, Hotcherl·2020·Genes
DOI 10.3390/genes11121445PMC PMC7760818
Open this paper in CoChat — free accountOpen PDF

Abstract

Realizing the promise of precision medicine in psychiatry is a laudable and beneficial endeavor, since it should markedly reduce morbidity and mortality and, in effect, alleviate the economic and social burden of psychiatric disorders. This review aims to summarize important issues on pharmacogenomics in psychiatry that have laid the foundation towards personalized pharmacotherapy and, in a broader sense, precision medicine. We present major pharmacogenomic biomarkers and their applications in a variety of psychiatric disorders, such as depression, attention-deficit/hyperactivity disorder (ADHD), narcolepsy, schizophrenia, and bipolar disorder. In addition, we extend the scope into epilepsy, since antiepileptic drugs are widely used to treat psychiatric disorders, although epilepsy is conventionally considered to be a neurological disorder.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/genes11121445

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Some stimulants such as amphetamines and non-stimulants such as atomoxetine have been reported to be substrates of cytochrome P450s, and their performance has been linked to CYP2D6 genotype.

    “Some stimulants, such as amphetamines, and non-stimulants, such as atomoxetine, have been reported to be substrates of cytochrome P450s, and their performance has been linked to CYP2D6 genotype [41, 42].”

    From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [41]

    Section 5.2 says atomoxetine is metabolized by CYP2D6 and that poor metabolizers may have different therapeutic outcomes or adverse effects. Section 5.1 says CYP2D6 metabolizes amphetamine, but only suggests its metabolism may vary across populations; it does not link amphetamine's clinical performance to CYP2D6 genotype. Page numbers are not available in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 121

  1. [3]Clous E. Beerthuizen K. Ponsen K.J. Luitse J. Olff M. Goslings C. Trauma and psychiatric disorders: A systematic review J. Trauma Acute Care Surg. 2017 82 794 801 10.1097/TA.0000000000001371 28129262 · DOI
  2. [4]Lozupone M. Seripa D. Stella E. La Montagna M. Solfrizzi V. Quaranta N. Veneziani F. Cester A. Sardone R. Bonfiglio C. Innovative biomarkers in psychiatric disorders: A major clinical challenge in psychiatry Expert Rev. Proteom. 2017 14 809 824 10.1080/14789450.2017.1375857 28870126 · DOI
  3. [5]Eichelbaum M. Ingelman-Sundberg M. Evans W.E. Pharmacogenomics and individualized drug therapy Annu. Rev. Med. 2006 57 119 137 10.1146/annurev.med.56.082103.104724 16409140 · DOI
  4. [6]Lauschke V.M. Zhou Y. Ingelman-Sundberg M. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity Pharmacol. Ther. 2019 197 122 152 10.1016/j.pharmthera.2019.01.002 30677473 PMC6527860 · DOI
  5. [7]Sullivan P.F. Agrawal A. Bulik C.M. Andreassen O.A. Børglum A.D. Breen G. Cichon S. Edenberg H.J. Faraone S.V. Gelernter J. Psychiatric genomics: An update and an agenda Am. J. Psychiatry 2018 175 15 27 10.1176/appi.ajp.2017.17030283 28969442 PMC5756100 · DOI · Paper page
  6. [8]Hung S.-I. Chung W.-H. Jee S.-H. Chen W.-C. Chang Y.-T. Lee W.-R. Hu S.-L. Wu M.-T. Chen G.-S. Wong T.-W. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions Pharm. Genom. 2006 16 297 306 10.1097/01.fpc.0000199500.46842.4a 16538176 · DOI
  7. [9]Dean L. Carbamazepine Therapy and HLA Genotype Medical Genetics Summaries National Center for Biotechnology Information Bethesda, MD, USA 2012 28520367
  8. [10]Fricke-Galindo I. LLerena A. Jung-Cook H. López-López M. Carbamazepine adverse drug reactions Expert Rev. Clin. Pharmacol. 2018 11 705 718 10.1080/17512433.2018.1486707 29898616 · DOI
  9. [11]Barbarino J.M. McGregor T.L. Altman R.B. Klein T.E. PharmGKB summary: Very important pharmacogene information for MT-RNR1 Pharm. Genom. 2016 26 558 10.1097/FPC.0000000000000247 PMC5083147 27654872 · DOI
  10. [12]Rahman S. Ecob R. Costello H. Sweeney M.G. Duncan A.J. Pearce K. Strachan D. Forge A. Davis A. Bitner-Glindzicz M. Hearing in 44–45 year olds with m.1555A > G, a genetic mutation predisposing to aminoglycoside-induced deafness: A population based cohort study BMJ Open 2012 2 10.1136/bmjopen-2011-000411 PMC3253422 22223843 · DOI
  11. [13]Van der Wouden C.H. van Rhenen M.H. Jama W.O. Ingelman-Sundberg M. Lauschke V.M. Konta L. Schwab M. Swen J.J. Guchelaar H.J. Development of the PGx-passport: A panel of actionable germline genetic variants for pre-emptive pharmacogenetic testing Clin. Pharmacol. Ther. 2019 106 866 873 10.1002/cpt.1489 31038729 PMC6771671 · DOI
  12. [17]Ross C.J. Visscher H. Sistonen J. Brunham L.R. Pussegoda K. Loo T.T. Rieder M.J. Koren G. Carleton B.C. Hayden M.R. The canadian pharmacogenomics network for drug safety: A model for safety pharmacology Thyroid 2010 20 681 687 10.1089/thy.2010.1642 20578893 · DOI
  13. [18]Swen J.J. Huizinga T.W. Gelderblom H. De Vries E.G. Assendelft W.J. Kirchheiner J. Guchelaar H.-J. Translating pharmacogenomics: Challenges on the road to the clinic PLoS Med. 2007 4 e209 10.1371/journal.pmed.0040209 17696640 PMC1945038 · DOI
  14. [19]Ehmann F. Caneva L. Prasad K. Paulmichl M. Maliepaard M. Llerena A. Ingelman-Sundberg M. Papaluca-Amati M. Pharmacogenomic information in drug labels: European medicines agency perspective Pharm. J. 2015 15 201 210 10.1038/tpj.2014.86 25707393 · DOI
  15. [20]Drozda K. Pacanowski M.A. Grimstein C. Zineh I. Pharmacogenetic labeling of FDA-approved drugs: A regulatory retrospective JACC Basic Transl. Sci. 2018 3 545 549 10.1016/j.jacbts.2018.06.001 30175278 PMC6115648 · DOI
  16. [22]Guengerich F.P. Cytochrome P450 research and the journal of biological chemistry J. Biol. Chem. 2019 294 1671 1680 10.1074/jbc.TM118.004144 29871932 PMC6364786 · DOI
  17. [23]Manikandan P. Nagini S. Cytochrome P450 structure, function and clinical significance: A review Curr. Drug Targets 2018 19 38 54 10.2174/1389450118666170125144557 28124606 · DOI
  18. [25]El-Mallakh R.S. Roberts R.J. El-Mallakh P.L. Findlay L.J. Reynolds K.K. Pharmacogenomics in psychiatric practice Clin. Lab. Med. 2016 36 507 523 10.1016/j.cll.2016.05.001 27514465 · DOI
  19. [26]Gaedigk A. Sangkuhl K. Whirl-Carrillo M. Klein T. Leeder J.S. Prediction of CYP2D6 phenotype from genotype across world populations Genet. Med. 2017 19 69 76 10.1038/gim.2016.80 27388693 PMC5292679 · DOI
  20. [27]LLerena A. Naranjo M.E.G. Rodrigues-Soares F. Penas-LLedo E.M. Farinas H. Tarazona-Santos E. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations Expert Opin. Drug Metab. Toxicol. 2014 10 1569 1583 10.1517/17425255.2014.964204 25316321 · DOI
  21. [28]Oshiro C. Thorn C.F. Roden D.M. Klein T.E. Altman R.B. KCNH2 pharmacogenomics summary Pharm. Genom. 2010 20 775 10.1097/FPC.0b013e3283349e9c 20150828 PMC3086352 · DOI
  22. [29]Gaedigk A. Gotschall R.R. Forbes N.S. Simon S.D. Kearns G.L. Leeder J.S. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data Pharm. Genom. 1999 9 669 682 10.1097/01213011-199912000-00002 10634130 · DOI
  23. [30]Bradford L.D. CYP2D6 allele frequency in european caucasians, Asians, Africans and their descendants Pharmacogenomics 2002 3 229 243 10.1517/14622416.3.2.229 11972444 · DOI
  24. [31]Yokota H. Tamura S. Furuya H. Kimura S. Watanabe M. Kanazawa I. Kondo I. Gonzalez F.J. Evidence for a new variant CYP2D6 allele CYP2D6J in a japanese population associated with lower In Vivo rates of sparteine metabolism Pharmacogenetics 1993 3 256 263 10.1097/00008571-199310000-00005 8287064 · DOI
  25. [32]Sistonen J. Sajantila A. Lao O. Corander J. Barbujani G. Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure Pharm. Genom. 2007 17 93 101 17301689
  26. [33]Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P 450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity Pharm. J. 2005 5 6 13 15492763
  27. [34]Ingelman-Sundberg M. Sim S.C. Gomez A. Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol. Ther. 2007 116 496 526 10.1016/j.pharmthera.2007.09.004 18001838 · DOI
  28. [35]Schroth W. Hamann U. Fasching P.A. Dauser S. Winter S. Eichelbaum M. Schwab M. Brauch H. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratification Clin. Cancer Res. 2010 16 4468 4477 10.1158/1078-0432.CCR-10-0478 20515869 · DOI
  29. [36]De Vos A. Van Der Weide J. Loovers H. Association between CYP2C19* 17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients Pharm. J. 2011 11 359 367 10.1038/tpj.2010.39 20531370 · DOI
  30. [37]Steimer W. Zopf K. von Amelunxen S. Pfeiffer H. Bachofer J. Popp J. Messner B. Kissling W. Leucht S. Amitriptyline or not, that is the question: Pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy Clin. Chem. 2005 51 376 385 10.1373/clinchem.2004.041327 15590749 · DOI
  31. [38]Hicks J. Swen J. Thorn C. Sangkuhl K. Kharasch E. Ellingrod V. Skaar T. Müller D. Gaedigk A. Stingl J. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants Clin. Pharmacol. Ther. 2013 93 402 408 10.1038/clpt.2013.2 23486447 PMC3689226 · DOI
  32. [39]Ma M.K. Woo M.H. Mcleod H.L. Genetic basis of drug metabolism Am. J. Health-Syst. Pharm. 2002 59 2061 2069 10.1093/ajhp/59.21.2061 12434718 · DOI
  33. [40]Błaszczyk B. Czuczwar S.J. Epilepsy coexisting with depression Pharmacol. Rep. 2016 68 1084 1092 10.1016/j.pharep.2016.06.011 27634589 · DOI
  34. [41]Feighner J.P. Mechanism of action of antidepressant medications Proceedings of the Assessing Antidepressant Efficacy: A Reexamination American Psychological Association Phoenix, AZ, USA 1998
  35. [43]Ramamoorthy S. Leibach F. Mahesh V. Ganapathy V. Partial purification and characterization of the human placental serotonin transporter Placenta 1993 14 449 461 10.1016/S0143-4004(05)80465-5 8248037 · DOI
  36. [44]Lesch K.-P. Wolozin B. Estler H. Murphy D. Riederer P. Isolation of a cDNA encoding the human brain serotonin transporter J. Neural Transm. Gen. Sect. JNT 1993 91 67 72 10.1007/BF01244919 8452685 · DOI
  37. [45]Lesch K.-P. Bengel D. Heils A. Sabol S.Z. Greenberg B.D. Petri S. Benjamin J. Müller C.R. Hamer D.H. Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region Science 1996 274 1527 1531 10.1126/science.274.5292.1527 8929413 · DOI · Paper page
  38. [46]Clarke H. Flint J. Attwood A. Munafo M. Association of the 5-HTTLPR genotype and unipolar depression: A meta-analysis Psychol. Med. 2010 40 1767 1778 10.1017/S0033291710000516 20380781 · DOI
  39. [48]Taylor M.J. Sen S. Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region Biol. Psychiatry 2010 68 536 543 10.1016/j.biopsych.2010.04.034 20615496 PMC2929304 · DOI
  40. [49]Kato M. Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder Mol. Psychiatry 2010 15 473 500 10.1038/mp.2008.116 18982004 · DOI · Paper page
  41. [50]Mellström B. Säwe J. Bertilsson L. Sjöqvist F. Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers Clin. Pharmacol. Ther. 1986 39 369 371 10.1038/clpt.1986.56 3956053 · DOI
  42. [51]Hicks J.K. Sangkuhl K. Swen J.J. Ellingrod V.L. Müller D.J. Kazu S. Bishop J.R. Kharasch E.D. Skaar T.C. Gaedigk A. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Tricyclic Antidepressants: 2016 Update Clin. Pharmacol. Ther. 2017 102 37 44 10.1002/cpt.597 27997040 PMC5478479 · DOI
  43. [52]Stern S.L. Ribner H.S. Cooper T.B. Nelson L.D. Johnson M.H. Suckow R.F. 2-Hydroxydesipramine and desipramine plasma levels and electrocardiographic effects in depressed younger adults J. Clin. Psychopharmacol. 1991 11 93 98 10.1097/00004714-199104000-00004 2056147 · DOI
  44. [53]Schneider L.S. Cooper T.B. Severson J.A. Zemplenyi T. Sloane R.B. Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients J. Clin. Psychopharmacol. 1988 8 402 408 10.1097/00004714-198812000-00004 3069881 · DOI
  45. [54]Suwała J. Machowska M. Wiela-Hojeńska A. Venlafaxine pharmacogenetics: V comprehensive review Pharmacogenomics 2019 20 829 845 10.2217/pgs-2019-0031 31368838 · DOI
  46. [55]Venlafaxine, Desvenlafaxine LiverTox: Clinical and Research Information on Drug-Induced Liver Injury National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD, USA 2012 31643176
  47. [57]Sangkuhl K. Stingl J.C. Turpeinen M. Altman R.B. Klein T.E. PharmGKB summary: Venlafaxine pathway Pharm. Genom. 2014 24 62 10.1097/FPC.0000000000000003 PMC4098656 24128936 · DOI
  48. [58]Berm E. Kok R. Hak E. Wilffert B. Relation between CYP2D6 genotype, phenotype and therapeutic drug concentrations among nortriptyline and venlafaxine users in old age psychiatry Pharmacopsychiatry 2016 49 186 190 10.1055/s-0042-105443 27101231 · DOI
  49. [59]Berm E.J. Hak E. Postma M. Boshuisen M. Breuning L. Brouwers J.R. Dhondt T. Jansen P.A. Kok R.M. Maring J.G. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: Study protocol for a pragmatic randomized controlled trial (CYSCEtrial) Trials 2015 16 37 10.1186/s13063-015-0561-0 25636328 PMC4328880 · DOI
  50. [60]Waade R.B. Hermann M. Moe H.L. Molden E. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups Eur. J. Clin. Pharmacol. 2014 70 933 940 10.1007/s00228-014-1696-8 24858822 · DOI
  51. [61]Shams M. Arneth B. Hiemke C. Dragicevic A. Müller M. Kaiser R. Lackner K. Härtter S. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine J. Clin. Pharm. Ther. 2006 31 493 502 10.1111/j.1365-2710.2006.00763.x 16958828 · DOI
  52. [62]Johnson E.M. Whyte E. Mulsant B.H. Pollock B.G. Weber E. Begley A.E. Reynolds C.F. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression Am. J. Geriatr. Psychiatry 2006 14 796 802 10.1097/01.JGP.0000204328.50105.b3 16943176 · DOI
  53. [63]Montané Jaime L.K. Paul J. Lalla A. Legall G. Gaedigk A. Impact of CYP2D6 on venlafaxine metabolism in trinidadian patients with major depressive disorder Pharmacogenomics 2018 19 197 212 10.2217/pgs-2017-0142 29327975 · DOI
  54. [64]Olson M.C. Maciel A. Gariepy J.F. Cullors A. Saldivar J.-S. Taylor D. Centeno J. Garces J.A. Vaishnavi S. Clinical impact of pharmacogenetic-guided treatment for patients exhibiting neuropsychiatric disorders: A randomized controlled trial Prim. Care Companion CNS Disord. 2017 19 10.4088/PCC.16m02036 28314093 · DOI
  55. [65]Lloret-Linares C. Daali Y. Chevret S. Nieto I. Molière F. Courtet P. Galtier F. Richieri R.-M. Morange S. Llorca P.-M. Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study) BMC Pharmacol. Toxicol. 2017 18 1 12 10.1186/s40360-017-0173-2 29115994 PMC5678760 · DOI
  56. [66]Burke W. Thummel K. Telling it like it is: A call for accurate pharmacogenetic labeling JAMA Intern. Med. 2014 174 1945 10.1001/jamainternmed.2014.3276 25317574 PMC4250298 · DOI
  57. [67]Watanabe Y. Asami Y. Hirano Y. Kuribayashi K. Itamura R. Imaeda T. Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: Exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan Neuropsychiatr. Dis. Treat. 2018 14 1261 10.2147/NDT.S146428 29844674 PMC5962303 · DOI
  58. [68]Taranu A. Colle R. Gressier F. El Asmar K. Becquemont L. Corruble E. Verstuyft C. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings? Pharmacogenomics 2017 18 639 650 10.2217/pgs-2017-0003 28480819 · DOI
  59. [69]Van der Schans J. Hak E. Postma M. Breuning L. Brouwers J.R. Ditters K. Jansen P.A. Kok R.M. Maring J.G. van Marum R. Effects of pharmacogenetic screening for CYP2D6 among elderly starting therapy with nortriptyline or venlafaxine: A pragmatic randomized controlled trial (CYSCE Trial) J. Clin. Psychopharmacol. 2019 39 583 590 10.1097/JCP.0000000000001129 31688392 · DOI
  60. [70]Maron E. Nutt D. Biological markers of generalized anxiety disorder Dialogues Clin. Neurosci. 2017 19 147 10.1176/appi.focus.16205 28867939 PMC5573559 · DOI · Paper page
  61. [72]Agrawal N. Faruqui R. Bodani M. Oxford Textbook of Neuropsychiatry Oxford University Press Oxford, UK 2020
  62. [73]Polanczyk G. De Lima M.S. Horta B.L. Biederman J. Rohde L.A. The worldwide prevalence of ADHD: A systematic review and metaregression analysis Am. J. Psychiatry 2007 164 942 948 10.1176/ajp.2007.164.6.942 17541055 · DOI · Paper page
  63. [77]Moreira-Maia C.R. Massuti R. Tessari L. Campani F. Akutagava-Martins G.C. Cortese S. Rohde L.A. Are ADHD medications under or over prescribed worldwide?: Protocol for a systematic review and meta-analysis Medicine 2018 97 10.1097/MD.0000000000010923 29901582 PMC6023876 · DOI
  64. [79]Subcommittee on Attention-Deficit/Hyperactivity Disorder Steering Committee on Quality Improvement and Management ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents Am. Acad. Pediatrics 2011 128 1007 1022 PMC4500647 22003063
  65. [80]Hutchison S.L. Ghuman J.K. Ghuman H.S. Karpov I. Schuster J.M. Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: A review Ther. Adv. Psychopharmacol. 2016 6 317 334 10.1177/2045125316647686 27721971 PMC5036135 · DOI
  66. [83]Barateau L. Lopez R. Dauvilliers Y. Treatment options for narcolepsy CNS Drugs 2016 30 369 379 10.1007/s40263-016-0337-4 27155860 · DOI
  67. [85]Castells X. Blanco-Silvente L. Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults Cochrane Database Syst. Rev. 2018 8 10.1002/14651858.CD007813.pub3 PMC6513464 30091808 · DOI · Paper page
  68. [86]Hodgkins P. Shaw M. McCarthy S. Sallee F.R. The pharmacology and clinical outcomes of amphetamines to treat ADHD CNS Drugs 2012 26 245 268 10.2165/11599630-000000000-00000 22329564 · DOI
  69. [87]Bach M.V. Coutts R.T. Baker G.B. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives Xenobiotica 1999 29 719 732 10.1080/004982599238344 10456690 · DOI
  70. [88]Pratt V.M. McLeod H.L. Rubinstein W.S. Scott S.A. Dean L.C. Kattman B.L. Malheiro A.J. Medical Genetics Summaries [Internet] National Center for Biotechnology Information Bethesda, MD, USA 2012 28520340
  71. [90]Brown J.T. Bishop J.R. Atomoxetine pharmacogenetics: Associations with pharmacokinetics, treatment response and tolerability Pharmacogenomics 2015 16 1513 1520 10.2217/PGS.15.93 26314574 · DOI
  72. [92]Minzenberg M.J. Carter C.S. Modafinil: A review of neurochemical actions and effects on cognition Neuropsychopharmacology 2008 33 1477 1502 10.1038/sj.npp.1301534 17712350 · DOI · Paper page
  73. [93]Schwartz J.C. The histamine H3 receptor: From discovery to clinical trials with pitolisant Br. J. Pharmacol. 2011 163 713 721 10.1111/j.1476-5381.2011.01286.x 21615387 PMC3111674 · DOI
  74. [95]Syed Y.Y. Pitolisant: First global approval Drugs 2016 76 1313 1318 10.1007/s40265-016-0620-1 27438291 · DOI
  75. [96]Hudepohl N.S. Nasrallah H.A. Antipsychotic drugs Handbook of Clinical Neurology Elsevier Amsterdam, The Netherlands 2012 Volume 106 657 667 22608650
  76. [97]Lally J. MacCabe J.H. Antipsychotic medication in schizophrenia: A review Br. Med. Bull. 2015 114 169 179 10.1093/bmb/ldv017 25957394 · DOI
  77. [98]Nandra K.S. Agius M. The differences between typical and atypical antipsychotics: The effects on neurogenesis Psychiatr. Danub. 2012 24 S95 S99 22945197
  78. [99]Beaulieu J.-M. Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors Pharmacol. Rev. 2011 63 182 217 10.1124/pr.110.002642 21303898 · DOI · Paper page
  79. [100]Salem H. Pigott T. Zhang X.Y. Zeni C.P. Teixeira A.L. Antipsychotic-induced Tardive dyskinesia: From biological basis to clinical management Expert Rev. Neurother. 2017 17 883 894 10.1080/14737175.2017.1361322 28750568 · DOI
  80. [101]Dean K. Murray R.M. Environmental risk factors for psychosis Dialogues Clin. Neurosci. 2005 7 69 16060597 PMC3181718
  81. [102]Allen N.C. Bagade S. McQueen M.B. Ioannidis J.P. Kavvoura F.K. Khoury M.J. Tanzi R.E. Bertram L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: The SzGene database Nat. Genet. 2008 40 827 10.1038/ng.171 18583979 · DOI · Paper page
  82. [104]Ripke S. Neale B. Schizophrenia working group of the psychiatric genomics consortium. Biological insights from 108 schizophrenia-associated genetic loci Nature 2014 511 421 427 25056061 PMC4112379
  83. [105]Scheggia D. Mastrogiacomo R. Mereu M. Sannino S. Straub R.E. Armando M. Managò F. Guadagna S. Piras F. Zhang F. Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment Nat. Commun. 2018 9 1 11 10.1038/s41467-018-04711-w 29891954 PMC5995960 · DOI
  84. [106]Leggio G. Torrisi S. Mastrogiacomo R. Mauro D. Chisari M. Devroye C. Scheggia D. Nigro M. Geraci F. Pintori N. The epistatic interaction between the dopamine D3 receptor and dysbindin-1 modulates higher-order cognitive functions in mice and humans Mol. Psychiatry 2019 24 1 4 10.1038/s41380-019-0511-4 31492942 · DOI
  85. [107]Sriretnakumar V. Huang E. Müller D.J. Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: An update Expert Opin. Drug Metab. Toxicol. 2015 11 1709 1731 10.1517/17425255.2015.1075003 26364648 · DOI
  86. [109]Van Troostwijk L.J.D. Koopmans R.P. Vermeulen H.D. Guchelaar H.-J. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients Eur. J. Pharm. Sci. 2003 20 451 457 10.1016/j.ejps.2003.09.010 14659489 · DOI
  87. [110]Sampson S. Hosalli P. Furtado V.A. Davis J.M. Risperidone (depot) for schizophrenia Cochrane Database Syst. Rev. 2016 10.1002/14651858.CD004161.pub2 PMC10493848 27078222 · DOI
  88. [111]Puangpetch A. Vanwong N. Nuntamool N. Hongkaew Y. Chamnanphon M. Sukasem C. CYP2D6 polymorphisms and their influence on risperidone treatment Pharm. Pers. Med. 2016 9 131 10.2147/PGPM.S107772 PMC5138038 27942231 · DOI
  89. [112]Heide J. Zhang F. Bigos K.L. Mann S.A. Carr V.J. Shannon Weickert C. Green M.J. Weinberger D.R. Vandenberg J.I. Differential response to risperidone in schizophrenia patients by KCNH2 genotype and drug metabolizer status Am. J. Psychiatry 2016 173 53 59 10.1176/appi.ajp.2015.14050653 26481172 · DOI
  90. [113]Wang X. Su Y. Yan H. Huang Z. Huang Y. Yue W. Association study of KCNH7 polymorphisms and individual responses to risperidone treatment in schizophrenia Front. Psychiatry 2019 10 633 10.3389/fpsyt.2019.00633 31543842 PMC6728906 · DOI
  91. [114]Thanacoody R.H. Thioridazine: The good and the bad Recent Pat. Anti-Infect. Drug Discov. 2011 6 92 98 10.2174/157489111796064588 21548877 · DOI
  92. [115]Dean L. Thioridazine Therapy and CYP2D6 Genotypes Medical Genetics Summaries [Internet] National Center for Biotechnology Information Bethesda, MD, USA 2017 28520378
  93. [116]Grande I. Berk M. Birmaher B. Vieta E. Bipolar disorder Lancet 2016 387 1561 1572 10.1016/S0140-6736(15)00241-X 26388529 · DOI · Paper page
  94. [117]Miller T.H. Bipolar Disorder Prim. Care 2016 43 269 284 10.1016/j.pop.2016.02.003 27262007 · DOI
  95. [118]Fisher R.S. Boas W.V.E. Blume W. Elger C. Genton P. Lee P. Engel J. Jr. Epileptic seizures and epilepsy: Definitions proposed by the international league against epilepsy (ILAE) and the International bureau for epilepsy (IBE) Epilepsia 2005 46 470 472 10.1111/j.0013-9580.2005.66104.x 15816939 · DOI
  96. [119]Thurman D.J. Beghi E. Begley C.E. Berg A.T. Buchhalter J.R. Ding D. Hesdorffer D.C. Hauser W.A. Kazis L. Kobau R. Standards for epidemiologic studies and surveillance of epilepsy Epilepsia 2011 52 Suppl. 7 2 26 10.1111/j.1528-1167.2011.03121.x 21899536 · DOI
  97. [120]Balestrini S. Sisodiya S.M. Pharmacogenomics in epilepsy Neurosci. Lett. 2018 667 27 39 10.1016/j.neulet.2017.01.014 28082152 PMC5846849 · DOI
  98. [122]Niespodziany I. Rigo J.M. Moonen G. Matagne A. Klitgaard H. Wolff C. Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons Epilepsia 2017 58 e157 e161 10.1111/epi.13890 28850675 · DOI
  99. [124]Chung W.-H. Hung S.-I. Hong H.-S. Hsih M.-S. Yang L.-C. Ho H.-C. Wu J.-Y. Chen Y.-T. A marker for Stevens-Johnson syndrome Nature 2004 428 486 10.1038/428486a 15057820 · DOI
  100. [126]Nakamura F. Suzuki S. Nishimura S. Yagi K. Seino M. Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture Epilepsia 1996 37 728 735 10.1111/j.1528-1157.1996.tb00643.x 8764810 · DOI
  101. [127]Kosaki K. Tamura K. Sato R. Samejima H. Tanigawara Y. Takahashi T. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam Brain Dev. 2004 26 530 534 10.1016/j.braindev.2004.02.010 15533655 · DOI · Paper page
  102. [128]Seo T. Nagata R. Ishitsu T. Murata T. Takaishi C. Hori M. Nakagawa K. Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy Pharmacogenomics 2008 9 10.2217/14622416.9.5.527 18466100 · DOI
  103. [130]Huddart R. Leeder J.S. Altman R.B. Klein T.E. PharmGKB summary: Clobazam pathway, pharmacokinetics Pharm. Genom. 2018 28 110 10.1097/FPC.0000000000000327 PMC5914180 29517622 · DOI
  104. [132]Vossler D.G. Weingarten M. Gidal B.E. Committee A.E.S.T. Summary of antiepileptic drugs available in the United States of America Epilepsy Curr. 2018 18 1 26 10.5698/1535-7597.18.4s1.1 30233275 PMC6130739 · DOI
  105. [134]Errington A.C. Stöhr T. Heers C. Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels Mol. Pharmacol. 2008 73 157 169 10.1124/mol.107.039867 17940193 · DOI
  106. [135]Abou-Khalil B.W. Oxcarbazepine and carbamazepine: Expected and unexpected differences and similarities Epilepsy Curr. 2007 7 74 76 10.1111/j.1535-7511.2007.00176.x 17520080 PMC1874328 · DOI
  107. [136]Susan M. Faulds D. Oxcarbazepine, a revidw of its pharmacology and the rapeutic potential in epilepsy, trigeminal neuralgia and affectire disorders Drugs 1992 43 873 888 1379159
  108. [137]Grant S.M. Faulds D. Oxcarbazepine Drugs 1992 43 873 888 10.2165/00003495-199243060-00007 1379159 · DOI
  109. [140]Sutrisna E. Personalized medicine phenytoin therapy J. Pharm. Biomed. Sci. 2017 7 3 5 10.3892/br.2017.922 · DOI
  110. [142]Zhu M.-M. Li H.-L. Shi L.-H. Chen X.-P. Luo J. Zhang Z.-L. The pharmacogenomics of valproic acid J. Hum. Genet. 2017 62 1009 1014 10.1038/jhg.2017.91 28878340 · DOI
  111. [143]Weinshilboum R. Wang L. Pharmacogenomics: Bench to bedside Nat. Rev. Drug Discov. 2004 3 739 748 10.1038/nrd1497 15340384 · DOI
  112. [144]Lazaridis K.N. Mcallister T.M. Babovic-Vuksanovic D. Beck S.A. Borad M.J. Bryce A.H. Chanan-Khan A.A. Ferber M.J. Fonseca R. Johnson K.J. Implementing individualized medicine into the medical practice Am. J. Med. Genet. Part C Semin. Med. Genet. 2014 166C 15 23 10.1002/ajmg.c.31387 24616301 · DOI
  113. [145]Evans W.E. Relling M.V. Moving towards individualized medicine with pharmacogenomics Nature 2004 429 464 468 10.1038/nature02626 15164072 · DOI
  114. [146]Collins F.S. Varmus H. A new initiative on precision medicine N. Engl. J. Med. 2015 372 793 795 10.1056/NEJMp1500523 25635347 PMC5101938 · DOI · Paper page
  115. [147]Iniesta R. Stahl D. McGuffin P. Machine learning, statistical learning and the future of biological research in psychiatry Psychol. Med. 2016 46 2455 2465 10.1017/S0033291716001367 27406289 PMC4988262 · DOI
  116. [148]Lane H.-Y. Tsai G.E. Lin E. Assessing gene-gene interactions in pharmacogenomics Mol. Diagn. Ther. 2012 16 15 27 10.1007/BF03256426 22352452 · DOI
  117. [149]Lin E. Hwang Y. Liang K.-H. Chen E.Y. Pattern-recognition techniques with haplotype analysis in pharmacogenomics Pharmacogenomics 2007 8 10.2217/14622416.8.1.75 17187511 · DOI
  118. [150]Russell S.J. Norvig P. Artificial Intelligence: A Modern Approach. Malaysia Pearson Education Limited London, UK 2016
  119. [151]Bzdok D. Meyer-Lindenberg A. Machine learning for precision psychiatry: Opportunities and challenges Biol. Psychiatry Cogn. Neurosci. Neuroimaging 2018 3 223 230 10.1016/j.bpsc.2017.11.007 29486863 · DOI
  120. [152]Fernandes B.S. Williams L.M. Steiner J. Leboyer M. Carvalho A.F. Berk M. The new field of “precision psychiatry” BMC Med. 2017 15 1 7 10.1186/s12916-017-0849-x 28403846 PMC5390384 · DOI
  121. [153]Lin E. Lin C.-H. Lane H.-Y. Precision psychiatry applications with pharmacogenomics: Artificial intelligence and machine learning approaches Int. J. Mol. Sci. 2020 21 969 10.3390/ijms21030969 32024055 PMC7037937 · DOI

Cited by

Sorted by citations

Authors
Kam, H., & Jeong, H.
Affiliations
Ewha Womans University (KR)
Corresponding author
Jeong, Hotcherl
ORCID
Venue
Genes
Publisher
MDPI AG
Published
2020-11-30
Volume
11
Issue
12
Pages
1445
ISSN
2073-4425 (ISSN-L)
DOI
10.3390/genes11121445
PMC
PMC7760818
OpenAlex
W3107448205
Cited by
37
References
9
Citations by year
2026: 9 · 2025: 4 · 2024: 4 · 2023: 10 · 2022: 5 · 2021: 5
FWCI
0.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Genes (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
pharmacogenomics, pharmacogenomic biomarkers, precision medicine, individualized drug therapy, mental illness, depression, attention deficit hyperactivity disorder, narcolepsy, schizophrenia, bipolar disorder, epilepsy, antiepileptic drugs
MeSH terms
Anticonvulsants, Mental Disorders, Epilepsy, Humans, Pharmacogenetics, Psychiatry, Biomarkers, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review